NCT05514496View on ClinicalTrials.gov

A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

December 1, 2025

Conditions
EGFR Mutation-Related Tumors
Interventions
DRUG

NX-019

NX-019 will be administered orally.

Trial Locations (12)

10002

National Taiwan University Cancer Center, Taipei City

22031

NEXT Virginia, Fairfax

22903

University Of Virginia Comprehensive Cancer Center, Charlottesville

55101

HealthPartners Cancer Center at Regions Hospital, Saint Paul

55426

HealthPartners Frauenshuh Cancer Center, Saint Louis Park

91010

City of Hope Comprehensive Cancer Center - Duarte, Duarte

92618

City of Hope Orange County Lennar Foundation Cancer Center, Irvine

92648

City of Hope - Seacliff, Huntington Beach

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Nalo Therapeutics Inc.

INDUSTRY